Sign up to save your podcasts
Or
Share BPDCN – Expert Insight Into a Rare Blood Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
BPDCN – Expert Insight Into a Rare Blood Cancer
Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX
Recorded on December 11, 2018
Join Drs. Naveen Pemmaraju and Ken Miller as they discuss
the diagnosis, treatment, and management of blastic plasmacytoid dendritic cell
neoplasm (BPDCN), an often misdiagnosed and highly aggressive hematologic
malignancy. Dr. Pemmaraju is a hematologist/oncologist at MD Anderson Cancer
Center in Houston, TX. On this episode, Dr. Pemmaraju discusses the origin of
BPDCN, methods of diagnosing and treating this rare disease, and the progress being
made in the field.
BPDCN Drug Updates: On December 21, 2018, the U.S. Food and Drug Administration (FDA) approved ELZONRIS (tagraxofusp) — the first treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older. For additional drug information, please visit: www.LLS.org/Drugs.
Naveen Pemmaraju, MD
Associate Professor
Department of Leukemia
MD Anderson Cancer Center
Houston, TX
View all episodes
By Blood Cancer United
4.8
1212 ratings
Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX
Recorded on December 11, 2018
Join Drs. Naveen Pemmaraju and Ken Miller as they discuss
the diagnosis, treatment, and management of blastic plasmacytoid dendritic cell
neoplasm (BPDCN), an often misdiagnosed and highly aggressive hematologic
malignancy. Dr. Pemmaraju is a hematologist/oncologist at MD Anderson Cancer
Center in Houston, TX. On this episode, Dr. Pemmaraju discusses the origin of
BPDCN, methods of diagnosing and treating this rare disease, and the progress being
made in the field.
BPDCN Drug Updates: On December 21, 2018, the U.S. Food and Drug Administration (FDA) approved ELZONRIS (tagraxofusp) — the first treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older. For additional drug information, please visit: www.LLS.org/Drugs.
Naveen Pemmaraju, MD
Associate Professor
Department of Leukemia
MD Anderson Cancer Center
Houston, TX
More shows like Treating Blood Cancers
View all
Hidden Brain
43,566 Listeners
NEJM This Week
319 Listeners
The Curbsiders Internal Medicine Podcast
3,343 Listeners
Up First from NPR
56,477 Listeners
The Bloodline with Blood Cancer United Podcast
46 Listeners
Core IM | Internal Medicine Podcast
1,147 Listeners
The ONS Podcast
206 Listeners
OncoPharm
187 Listeners
OncLive® On Air
22 Listeners
Blood Podcast
51 Listeners
ASTCT Talks
8 Listeners
The Mel Robbins Podcast
19,469 Listeners
Blood Cancer Talks
48 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
44 Listeners
WolverHeme Happy Hour
31 Listeners